China R&D Reader

The rapid growth of China’s economy is reflected in the dramatic rate of development observed in the nation’s biotech and pharmaceutical industry. Currently, there are more than 300 contract research organizations(CROs) and 5,000 pharmaceutical companies in China. The gross domestic product of China’s medical and pharmaceutical industry exceeded US$140 billion in 2008, compared to only [...]

At the beginning of 2009, IPO activity was at a standstill. But as the year progressed, and the threat of a complete financial disaster receded, a few companies managed to complete transactions that made them publicly owned entities, including several representatives of the China life science sector. We looked at how they fared, noticing a [...]

Syngenta Biotechnology, a division of the Swiss giant agribusiness company Syngenta (NYSE: SYT), has begun construction of an R&D center in Beijing. When the company announced its intention to build the center, it committed $100 million to developing the project over the next five years. The China facility will concentrate on evaluating genetic modifications for [...]

Beijing, China, December 9, 2009 – China Nuokang Bio-Pharmaceutical Inc. (NASDAQ: NKBP) (“Nuokang” or the “Company”), a leading China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products, announced today that its initial public offering of 5,000,000 American Depositary Shares (“ADSs”), each representing eight ordinary shares of the [...]

Simcere Pharmaceutical Group has acquired the China rights to a dual-mechanism cancer drug from OSI Pharmaceuticals, Inc. Simcere must first obtain regulatory approval for OSI-930, and then it will produce and market the drug in China. In the US, OSI-930 has completed a Phase I trial. Terms of the agreement were not disclosed.
OSI-930 is an [...]